Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 8 (3), 953-962

Serum Level of Soluble interleukin-2 Receptor Is Positively Correlated With Metabolic Tumor Volume on 18 F-FDG PET/CT in Newly Diagnosed Patients With Diffuse Large B-cell Lymphoma

Affiliations

Serum Level of Soluble interleukin-2 Receptor Is Positively Correlated With Metabolic Tumor Volume on 18 F-FDG PET/CT in Newly Diagnosed Patients With Diffuse Large B-cell Lymphoma

Hajime Senjo et al. Cancer Med.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin lymphoma. High total metabolic tumor volume (TMTV) calculated using 18 F-FDG PET/CT images at diagnosis predicts poor prognosis of patients with DLBCL. However, high cost and poor access to the imaging facilities hamper wider use of 18 F-FDG PET/CT. In order to explore a surrogate marker for TMTV, we evaluated the correlation between the serum levels of soluble interleukin-2 receptor (sIL-2R) and TMTV in 64 patients with DLBCL, and the results were verified in an independent validation cohort of 86 patients. Serum levels of sIL-2R were significantly correlated with TMTV. ROC analysis revealed that the cutoff value of TMTV ≥150 cm3 or sIL-2R ≥ 1300 U/mL could predict failure to achieve EFS24 with areas under the curve (AUC) 0.706 and 0.758, respectively. Each of TMTV ≥150 cm3 and sIL-2R ≥1300 U/mL was significantly associated with worse 5-year overall survival and event-free survival. Importantly, each of sIL-2R <1300 U/mL or TMTV <150 cm3 identified patients with favorable prognosis among NCCN-IPI high-intermediate and high-risk group. Serum level of sIL-2R represents a convenient surrogate marker to estimate metabolic tumor burden measured by 18 F-FDG PET/CT that can predict treatment outcomes of patients with DLBCL.

Keywords: diffuse large B-cell lymphoma; soluble interleukin-2 receptor; total metabolic tumor volume.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Kaplan‐Meier plots of OS (A) and EFS (B) of patients in the training cohort (n = 64)
Figure 2
Figure 2
Correlation of sIL‐2R level with TMTV. In the training population (n = 64), positive correlation between sIL‐2R and TMTV (Pearson R 2 = 0.490; P = 0.00004) (A) is shown. Positive correlation between sIL‐2R and TMTV (Pearson R 2 = 0.461; P = 0.00000631) (B) in the validation cohort (n = 86) is shown
Figure 3
Figure 3
ROC according to TMTV. In the training cohort, with regarding failure in achievement of 2‐year EFS as positive finding, ROC according to TMTV (A) is shown. Kaplan‐Meier plots of OS (B) and EFS (C) according to TMTV is shown (n = 64)
Figure 4
Figure 4
ROC according to sIL‐2R With regarding failure in achievement of 2‐y EFS as positive finding, a ROC according to sIL‐2R (A) is shown. Kaplan‐Meier plots of OS (B) and EFS (C) according to sIL‐2R were shown
Figure 5
Figure 5
Impacts of TMTV and sIL‐2R levels in patients with High and High‐intermediate risk by NCCN‐IPI. Kaplan‐Meier plots of OS (A) and EFS (B) according to TMTV, OS (C) and EFS (D) according to sIL‐2R in patients with High risk (n = 29) and High‐intermediate risk (n = 20) stratified by NCCN‐IPI are shown

Similar articles

See all similar articles

References

    1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265‐276. - PMC - PubMed
    1. Pfreundschuh M. How I treat elderly patients with diffuse large B‐cell lymphoma. Blood. 2010;116(24):5103‐5110. - PubMed
    1. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R‐IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B‐cell lymphoma treated with R‐CHOP. Blood. 2007;109(5):1857‐1861. - PubMed
    1. Wieringa A, Boslooper K, Hoogendoorn M, Joosten P, Beerden T, Storm H, et al. Comorbidity is an independent prognostic factor in patients with advanced‐stage diffuse large B‐cell lymphoma treated with R‐CHOP: a population‐based cohort study. Br J Haematol. 2014;165(4):489‐496. - PubMed
    1. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby‐Thompson A, et al. An enhanced International Prognostic Index (NCCN‐IPI) for patients with diffuse large B‐cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837‐842. - PMC - PubMed

LinkOut - more resources

Feedback